Simpler Grants.gov #RFA-CA-27-001

NCI Solicits Innovative Technology Development Grants for Cancer Biospecimen Research

The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), is inviting grant applications for the development of innovative, early-stage technologies to improve the analysis, handling, and quality control of biospecimens in cancer research and clinical care. - Government Buyer: - National Institutes of Health (NIH) - National Cancer Institute (NCI) - Solicitation Focus: - Development of new, innovative technologies (not procurement of existing products) - Emphasis on early-stage, proof-of-concept or pilot studies - Technologies should address biospecimen analysis, targeting, probing, handling, or quality control - Applications should demonstrate high technical innovation and potential to accelerate or enhance cancer research, detection, diagnosis, treatment, or address cancer health disparities - Products/Services Requested: - No specific products, part numbers, or OEMs are listed; the opportunity is for technology development proposals - Notable Requirements: - Open to a wide range of applicants, including government, academic, nonprofit, and commercial organizations - Funding is provided as grants, not contracts for product purchase - Awards expected to range from $50,000 to $150,000 each, with approximately 17 awards anticipated - OEMs and Vendors: - No OEMs or vendors specified, as this is a technology development grant opportunity - Place of Performance: - National Institutes of Health (NIH)

Description

The National Cancer Institute (NCI) is soliciting grant applications to develop innovative technologies for analyzing, targeting, probing, handling, or quality control of biospecimens used in cancer research or clinical care. The focus is on early-stage projects proposing proof-of-concept or pilot studies to test feasibility of new methods, tools, assays, platforms, or instruments. Applications should demonstrate high technical innovation and potential to enhance research in cancer biology, detection, diagnosis, treatment, control, epidemiology, or address cancer health disparities. Technologies must be focused on cancer applications and are part of the NCI's Innovative Molecular Analysis Technologies (IMAT) Program.

View original listing